UA92670C2 - Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе - Google Patents

Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе

Info

Publication number: UA92670C2
Authority: UA; Ukraine
Prior art keywords: receptor antagonists; composition based; pharmaceutical use; mineralocorticoid receptor; pyrazoline compounds
Prior art date: 2006-10-31

Application number

UAA200903302A

Other languages

English (en)

Ukrainian (uk)

Inventor

Марвин Джей Мейэрс

Гресиэла Барбиэри Аргансет

Киянгйан Чен

Сюзан Ландис Гокерман

Скотт Аллен Лонг

Метью Виллиям Махони

Девид Брюс Рейтс

Джозеф Герас Рико

Original Assignee

Пфайзер Продактс Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-31

Filing date

2007-10-17

Publication date

2010-11-25

2007-10-17 Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.

2010-11-25 Publication of UA92670C2 publication Critical patent/UA92670C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UAA200903302A 2006-10-31 2007-10-17 Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе UA92670C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US86360606P	2006-10-31	2006-10-31

Publications (1)

Publication Number	Publication Date
UA92670C2 true UA92670C2 (ru)	2010-11-25

Family

ID=39027523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200903302A UA92670C2 (ru)	2006-10-31	2007-10-17	Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе

Country Status (40)

Country	Link
US (3)	US7781428B2 (ru)
EP (1)	EP2089367B1 (ru)
JP (1)	JP4977760B2 (ru)
KR (1)	KR101107800B1 (ru)
CN (1)	CN101541757A (ru)
AP (1)	AP2527A (ru)
AR (1)	AR063529A1 (ru)
AT (1)	ATE537151T1 (ru)
AU (1)	AU2007315884B2 (ru)
BR (1)	BRPI0717937A2 (ru)
CA (1)	CA2667966C (ru)
CL (1)	CL2007003154A1 (ru)
CO (1)	CO6160307A2 (ru)
CR (1)	CR10725A (ru)
CU (1)	CU23779B7 (ru)
CY (1)	CY1112311T1 (ru)
DK (1)	DK2089367T3 (ru)
EA (1)	EA016370B1 (ru)
ES (1)	ES2375877T3 (ru)
GE (1)	GEP20115239B (ru)
GT (1)	GT200700096A (ru)
HN (1)	HN2007000437A (ru)
HR (1)	HRP20120078T1 (ru)
IL (1)	IL198241A0 (ru)
MA (1)	MA30821B1 (ru)
MX (1)	MX2009004662A (ru)
MY (1)	MY145795A (ru)
NI (1)	NI200900071A (ru)
NO (1)	NO20091741L (ru)
NZ (1)	NZ575923A (ru)
PE (1)	PE20081472A1 (ru)
PL (1)	PL2089367T3 (ru)
PT (1)	PT2089367E (ru)
RS (2)	RS20090208A (ru)
SI (1)	SI2089367T1 (ru)
TN (1)	TN2009000160A1 (ru)
TW (1)	TWI357327B (ru)
UA (1)	UA92670C2 (ru)
UY (1)	UY30670A1 (ru)
WO (1)	WO2008053300A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI431010B (zh)	2007-12-19	2014-03-21	Lilly Co Eli	礦皮質素受體拮抗劑及使用方法
KR20130036171A (ko) *	2009-10-29	2013-04-11	브리스톨-마이어스 스큅 컴퍼니	트리시클릭 헤테로시클릭 화합물
EP2568986B1 (en)	2010-05-10	2016-01-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
CA2798831A1 (en)	2010-05-11	2011-11-17	Pfizer Inc.	Morpholine compounds as mineralocorticoid receptor antagonists
JP6180930B2 (ja)	2010-06-16	2017-08-16	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102372710A (zh)	2010-08-18	2012-03-14	山东轩竹医药科技有限公司	作为盐皮质激素受体拮抗剂的并环类化合物
WO2012048022A2 (en) *	2010-10-05	2012-04-12	Nova Southeastern University	Methods and compositions for therapeutic modulation of aldosterone levels in heart disease
MX367404B (es)	2014-06-30	2019-08-20	Astrazeneca Ab	Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
ES2846835T3 (es)	2015-10-13	2021-07-29	Inst Nat Sante Rech Med	Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
ES2973248T3 (es)	2016-07-26	2024-06-19	Inst Nat Sante Rech Med	Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
ES2859478T3 (es)	2016-09-02	2021-10-04	Bristol Myers Squibb Co	Compuestos heterocíclicos tricíclicos sustituidos
WO2019032631A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	Oxime ether compounds
WO2019032632A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	ALKYLPHENYL COMPOUNDS
WO2021180818A1 (en)	2020-03-11	2021-09-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
US20240366632A1 (en)	2021-08-31	2024-11-07	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of ocular rosacea
CN113679716B (zh)	2021-10-13	2024-03-26	史大永	溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) *	2022-01-04	2023-06-09	中山大学	一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1086068A (en) *	1964-09-02	1967-10-04	Ici Ltd	Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) *	1971-10-13	1973-04-11	Sandoz Sa	Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) *	1972-12-22	1974-06-11	Sandoz Ag	2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) *	1973-05-29	1974-10-22	Sandoz Ag	Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) *	1988-09-30	1989-09-12	Eastman Kodak Company	Thermally-transferable fluorescent diphenylpyrazolines
ES2098547T3 (es) *	1992-01-23	1997-05-01	Pfizer	Benzopirano y otros antagonistas de ltb4 relacionados.
GB9318691D0 (en)	1993-09-09	1993-10-27	Merck Sharp & Dohme	Therapeutic agents
AR006520A1 (es)	1996-03-20	1999-09-08	Astra Pharma Prod	Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
AU711539B2 (en) *	1996-09-05	1999-10-14	Astra Pharmaceuticals Limited	Novel aryl-pyridazines
JPH10273467A (ja) *	1997-01-29	1998-10-13	Snow Brand Milk Prod Co Ltd	新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it)	1997-06-05	1999-01-25	Geange Ltd	Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
EP1073435B1 (en)	1998-04-30	2004-07-07	Abbott GmbH & Co. KG	Substituted tricyclic pyrazole derivatives with protein kinase activity
US6432974B1 (en) *	2000-02-04	2002-08-13	Wyeth	Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
ATE448207T1 (de)	2002-03-08	2009-11-15	Merck & Co Inc	Mitotische kinesin-hemmer
WO2003078394A1 (en)	2002-03-15	2003-09-25	Eli Lilly And Company	Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en)	2002-06-26	2004-01-16	Lilly Co Eli	Tricyclic steroid hormone nuclear receptor modulators
AU2003257078B2 (en)	2002-08-02	2010-04-01	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of GSK-3
CA2496295C (en)	2002-09-18	2010-11-23	Michael John Munchhof	Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
JP2007500253A (ja)	2003-01-22	2007-01-11	イーライリリーアンドカンパニー	ステロイドホルモン核内受容体のインドール誘導体モジュレーター
WO2005066161A1 (en)	2003-12-19	2005-07-21	Eli Lilly And Company	Tricyclic steroid hormone nuclear receptor modulators
JP2007230869A (ja)	2004-04-05	2007-09-13	Takeda Chem Ind Ltd	アルドステロン受容体拮抗剤
WO2006010142A2 (en)	2004-07-14	2006-01-26	Ligand Pharmaceuticals, Inc.	Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
EP1773768B8 (en)	2004-07-30	2018-12-26	Exelixis, Inc.	Pyrrole derivatives as pharmaceutical agents
AU2006205220B2 (en)	2005-01-10	2012-09-13	Exelixis, Inc.	Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
EP1844768A1 (en)	2005-01-19	2007-10-17	Dainippon Sumitomo Pharma Co., Ltd.	Aromatic sulfone compound as aldosterone receptor modulator
AU2006212863A1 (en)	2005-02-10	2006-08-17	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors

2007
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en not_active Ceased
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active Expired - Fee Related
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 RS RS20120051A patent/RS52203B/sr unknown
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
2009
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
2012
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown

Also Published As

Publication number	Publication date
RS52203B (sr)	2012-10-31
CO6160307A2 (es)	2010-05-20
US7781428B2 (en)	2010-08-24
EP2089367B1 (en)	2011-12-14
HN2007000437A (es)	2011-01-17
KR20090060371A (ko)	2009-06-11
WO2008053300A1 (en)	2008-05-08
JP2010508257A (ja)	2010-03-18
RS20090208A (sr)	2010-06-30
GT200700096A (es)	2010-07-15
AU2007315884B2 (en)	2012-10-04
US20100280016A1 (en)	2010-11-04
CA2667966A1 (en)	2008-05-08
CR10725A (es)	2009-05-12
TWI357327B (en)	2012-02-01
TN2009000160A1 (fr)	2010-10-18
MY145795A (en)	2012-04-30
DK2089367T3 (da)	2012-02-06
EA200970341A1 (ru)	2009-10-30
PE20081472A1 (es)	2008-10-18
AU2007315884A1 (en)	2008-05-08
CL2007003154A1 (es)	2008-05-09
EP2089367A1 (en)	2009-08-19
IL198241A0 (en)	2009-12-24
NZ575923A (en)	2011-01-28
AP2527A (en)	2012-12-06
GEP20115239B (en)	2011-06-10
BRPI0717937A2 (pt)	2013-12-03
US20080167294A1 (en)	2008-07-10
TW200822924A (en)	2008-06-01
CN101541757A (zh)	2009-09-23
UY30670A1 (es)	2008-05-31
ATE537151T1 (de)	2011-12-15
ES2375877T3 (es)	2012-03-07
CU20090058A7 (es)	2011-07-11
CA2667966C (en)	2011-08-02
CU23779B7 (es)	2012-02-15
NI200900071A (es)	2010-03-08
US20120035131A1 (en)	2012-02-09
AP2009004822A0 (en)	2009-04-30
MA30821B1 (fr)	2009-10-01
SI2089367T1 (sl)	2012-02-29
NO20091741L (no)	2009-05-29
PL2089367T3 (pl)	2012-04-30
JP4977760B2 (ja)	2012-07-18
EA016370B1 (ru)	2012-04-30
CY1112311T1 (el)	2015-12-09
KR101107800B1 (ko)	2012-01-25
MX2009004662A (es)	2009-05-22
AR063529A1 (es)	2009-01-28
HRP20120078T1 (hr)	2012-02-29
PT2089367E (pt)	2012-02-01

Publication	Publication Date	Title
UA92670C2 (ru)	2010-11-25	Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
EA200801998A1 (ru)	2009-04-28	ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2008021851A3 (en)	2008-06-26	Novel compounds as antagonists or inverse agonists for opioid receptors
PL2054411T3 (pl)	2015-02-27	Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
ATE483707T1 (de)	2010-10-15	2-cyclopropylthiazolderivate
WO2008121348A3 (en)	2009-06-18	Peripheral opioid receptor antagonists and uses thereof
IL184932A0 (en)	2007-12-03	Glucagon receptor antagonists, preperation and therapeutic uses
PH12012501800A1 (en)	2012-12-10	2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
WO2007135527A3 (en)	2008-03-13	Benzimidazolyl compounds
ATE493386T1 (de)	2011-01-15	Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
MY143581A (en)	2011-05-31	Carboxamide derivatives as muscarinic receptor antagonists
GEP20135744B (en)	2013-02-11	Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2010001338A (es)	2010-04-21	Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
UA93709C2 (ru)	2011-03-10	12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA99787C2 (en)	2012-09-25	Lactams as beta secretase inhibitors
MX2010002171A (es)	2010-04-30	Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
MX353209B (es)	2018-01-08	Antagonistas d2, metodos de sintesis y metodos de uso.
WO2007050802A3 (en)	2007-11-22	Novel opioid antagonists
DE602006006712D1 (de)	2009-06-18	Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2009006010A (es)	2009-06-16	Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
ATE542795T1 (de)	2012-02-15	Benzylpiperazinderivate als motilin- rezeptorantagonisten
WO2008074803A8 (en)	2009-05-14	4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
TW200745122A (en)	2007-12-16	New compounds I
TW200714587A (en)	2007-04-16	Biphenyl compounds useful as muscarinic receptor antagonists
WO2009076408A3 (en)	2009-09-03	3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists